---
run_id: halo-evidence-vs-diagnosis-validation-v7-generic-advice-prompted-01
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: generic_advice_prompted
run_number: 1
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 105
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
condition_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
output_file: model-outputs/generic_advice_prompted.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `generic_advice_prompted`, run 1 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 105, on the frozen condition packet.

## Output

I recommend you advise the CEO to commit to the **Targeted Evidence Pass**.

### The Reasoning
You are currently staring at a "false positive." The upbeat story in the board packet is built on lagging indicators and vanity metrics that mask a fundamental lack of product-market fit at the user level.

1.  **The Revenue is Artificial:** 72% of your expansion revenue is tied to six-month discounts. This isn't "growth"; it is a loan taken against future renewals. You have essentially paid customers to try a feature they aren't yet finding indispensable.
2.  **The Usage is a Mirage:** A 44% increase in usage sounds great, but the distribution is skewed. Your "champions" (the people who buy the software) are using it, but the "reviewers" (the people who actually derive value from it) are abandoning it at a staggering rate (69% churn after week one).
3.  **The "Wedge" is a Leak:** Sales leadership believes they found a market wedge, but the evidence suggests they have found a *sales pitch* that works, not a *product* that works. Scaling broadly (Option 1) based on this data would be a catastrophic misallocation of capital. You would be hiring implementation teams to deploy a feature that front-line users are actively rejecting.
4.  **The Regulatory Wall:** In the insurance segment, the product is failing a "hard" requirement: auditability. In compliance, if a user cannot explain a decision to an auditor, the tool is not just "less useful"—it is a liability.

Option 3 (Narrowing focus) is premature because you don't yet know if the "explainability" problem is a solvable UI/UX issue or a fundamental limitation of your AI model. Option 2 is the only path that treats the current "success" as a hypothesis to be tested rather than a fact to be scaled.

### The Strongest Reason Against This Recommendation
**The "Momentum Trap" and Political Risk.**
The board and the CEO are currently experiencing a psychological high. They see NRR rising and a team that finally looks "disciplined." Recommending a "pause" to instrument data and stop discounts will be perceived by Sales and the CEO as "stepping on the brakes during a victory lap."

By choosing the Evidence Pass, you are intentionally introducing friction into a narrative of success. You risk being viewed as the "bottleneck" or the "pessimist" who is stalling a market opportunity, especially if the CEO is under pressure to show aggressive growth trajectories to the board.

### Observable Evidence That Would Change My Mind
I would pivot from the Evidence Pass to **Broad Scaling (Option 1)** if you can produce data showing that the "Champion" usage is actually the primary value driver.

Specifically: If the evidence pass reveals that the compliance operations champions are using Review Assist to generate high-level reporting and oversight that the *buyers* value more than the *reviewers* value the triage notes, then the product is not a "triage tool"—it is a "management dashboard."

If the value is in the **oversight** rather than the **execution**, the 31% front-line retention rate is irrelevant. In that specific scenario, the "market wedge" is real, but it's a different wedge than the one you think you're building. Until you distinguish between "user value" and "buyer value," scaling is a gamble, not a strategy.
